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Introduction: Small cell lung cancer (SCLC) is initially a chemo-
therapy-sensitive disease. Nevertheless, drug-resistance results in
disease recurrence in most patients. Many drugs, including antime-
tabolites, are active, but only minimal progress has been made in
improving survival times for those with advanced disease. Based on
the need to discover better systemic therapies, we conducted a phase
II study of pemetrexed in patients with relapsed SCLC.
Patients and Methods: Eligible patients had SCLC or poorly
differentiated neuroendocrine cancers of the lung, Eastern Cooper-
ative Oncology Group performance status of 0 to 2, and had received
less than or equal to two prior chemotherapy regimens (additional
targeted agents were allowed). Both chemotherapy-sensitive (re-
lapse 90 days from completion of first line therapy) and chemo-
therapy-resistant (progressive disease during or within 90 days from
completion of first line treatment) patients were eligible and ana-
lyzed separately. Pemetrexed was administered at 500 mg/m2 intra-
venously every 21 days for up to six cycles. All patients received
folic acid, vitamin B12, and steroid prophylaxis. The primary
objective of the trial was to estimate the clinical benefit rate
(complete plus partial response plus stable disease) in each group.
Results: From January 2005 to September 2005, 20 patients were
enrolled in the chemotherapy-sensitive arm and 23 patients in the
chemotherapy-resistant arm. The majority of patients were men, the
median age of the two groups were 62.5 and 65, respectively; 75%
had a performance status of 0 or 1, and more than 50% had received
more than one prior regimen. Grade 3/4 toxicities were as expected
for pemetrexed. Progressive disease was the best response in 16
patients (80%) in the chemo-sensitive group and 19 patients (83%)
in the chemo-refractory group. One patient had a partial response
and three had stable disease in each group.
Conclusion: Pemetrexed has minimal single agent activity in re-
lapsed SCLC.
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Small cell lung cancer (SCLC) accounts for approximately13 to 15% of lung cancers.1 The majority of patients
present with extensive stage (ES) with evidence of wide
spread metastases. Despite an initial response to chemother-
apy, patients with SCLC inevitably relapse and progress
resulting in death in nearly all patients. Over the past decade,
only minimal improvements have been made in the treatment
of ES SCLC.2 Many agents tested over the last three decades
have demonstrated some activity, but only topotecan is ap-
proved by the U.S. Food and Drug Administration to treat
SCLC in the second line setting. Unfortunately, therapy with
topotecan results in a median survival time of only 6 months,
and most patients do not respond even for short periods of
time.3 More effective therapies are desperately needed.
Some antifolates have demonstrated activity against
SCLC. For example, treatment with methotrexate resulted in
responses in 25 to 30% of patients in one study and was
frequently integrated into multidrug regimens against SCLC.4
In contrast, 5-fluorouracil had no activity against SCLC in
two studies.5,6
Pemetrexed (Alimta, Eli Lilly and Company, Indianap-
olis, IN) is a multitargeted antifolate agent, the primary
mechanism of which is inhibition of thymidylate synthase.7
Pemetrexed also inhibits other folate-dependent enzymes in-
volved in purine synthesis, including dihydrofolate reductase
and glycinamide ribonucleotide formyl transferase and is
U.S. Food and Drug Administration approved to treat patients
with advanced non-SCLC and mesothelioma. An in vitro
growth inhibition study by Chan et al.8 showed pemetrexed
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delayed growth of SCLC cell lines. A randomized phase II
trial by Socinski et al.9 evaluating cisplatin/pemetrexed or
carboplatin/pemetrexed combinations in patients with ES
SCLC suggested these were active combinations; however,
the single agent activity of pemetrexed had not been defined.
We, therefore, conducted a study of single agent pemetrexed
in patients with relapsed SCLC to characterize its activity.
PATIENTS AND METHODS
Patient Selection/Eligibility
Eligible patients had histologic or cytologic proof of
small cell cancers of any site or poorly differentiated neu-
roendocrine cancers of the lung. All patients had measurable
disease per the Response Evaluation Criteria in Solid Tumors
criteria and had adequate bone marrow function as defined by
absolute neutrophil count more than or equal to 1500/mm3,
platelet count more than or equal to 100,000/mm3 and hemo-
globin more than or equal to 8 g/dL, renal function (creatinine
clearance45 mL/min), and liver function (bilirubin1.0
upper limit of normal and aspartate aminotransferase 2.5 
upper limit of normal). Patients had an Eastern Cooperative
Oncology Group performance status of 0 to 2 and must have
received treatment with at least one but not more than two
prior chemotherapy regimens (including one regimen con-
taining a platinum agent). Patients who received radiation
must have completed their radiation at least 14 days before
being registered for the protocol.
Exclusion criteria included symptomatic central ner-
vous system metastasis, uncontrolled pleural effusions, preg-
nancy or lactation, inability or unwillingness to interrupt
aspirin or other nonsteroidal anti-inflammatory agents, un-
willingness to take folic acid or vitamin B12 supplementa-
tion, or medical problems of significant severity (e.g., unsta-
ble respiratory or cardiac disease). Patients previously treated
with pemetrexed were not eligible. The study was conducted
by the Hoosier Oncology Group, a community-based coop-
erative group. The protocol was approved through institu-
tional ethics review boards, and all patients provided written
informed consent before treatment.
Pretreatment studies included history and physical ex-
amination, complete blood count with differential, blood
chemistries, and a computed tomography scan of chest or
chest radiograph. On study evaluations (every 21 days) in-
cluded a limited history and physical examination, complete
blood count and blood chemistries, performance status eval-
uation, and toxicity rating. Disease assessment by chest
radiograph or computed tomography scan was performed
before each cycle of therapy to ensure patients with other
treatment options were not rapidly progressing.
Treatment Schedule
All patients received pemetrexed 500 mg/m2 intrave-
nously over approximately 10 minutes. Pemetrexed was re-
peated every 3 weeks for up to six cycles or until patients had
either progressive disease or intolerable side effects. Patients
received folic acid (350–1000 g oral daily) approximately 1
week before the first dose of pemetrexed and continued that
daily during treatment. Vitamin B12 was also given (1000 g
intramuscular injection) beginning 1 week before the first
dose of pemetrexed and was repeated every 9 weeks during
treatment. Dexamethasone (4 mg oral twice daily) was given
for 3 days every cycle beginning the day before pemetrexed.
Dose Modifications
Dose adjustments at the beginning of a subsequent
cycle were based on neutrophil and platelet nadir values from
the preceding cycle of therapy. An absolute neutrophil count
more than or equal to 1.5  109/L and platelet count more
than or equal to 100 109/L were required before the start of
a new cycle. If a patient developed neutropenic fever, or
thrombocytopenia with platelet count less than 50,000/m3
with any bleeding, treatment was resumed at 75% of previous
dose of pemetrexed. A 50% dose reduction was advised for
grade 3–4 mucositis. Treatment was resumed at 75% of the
previous dose for other grade 3–4 nonhematologic toxicities
(with the exception of alopecia, nausea, vomiting, or grade 3
transaminase elevations).
Statistical Considerations
The trial used a two-stage design and evaluated che-
motherapy-sensitive and chemotherapy-resistant patients sep-
arately. For chemotherapy-sensitive patients (those who re-
lapsed90 days from completion of first line therapy), a total
of 18 patients were to be accrued to the first stage. If more
than or equal to eight patients exhibit disease control (com-
plete response (CR), partial response (PR), stable disease
(SD)), the study was to be continued to the second stage and
an additional 28 patients were enrolled. If more than or equal
to 23 patients of the 46 total patients on this arm have
nonprogressive disease, the regimen was to be considered
worthy of further study in this population. For chemotherapy-
resistant patients (those who relapsed within 90 days from
completion of first line therapy), a total of 21 patients were to
be accrued to the first stage. Further recruitment was to
continue to the second stage if more than or equal to three
patients had a response, whereby 29 additional patients were
then to be enrolled. If more than or equal to eight patients of
50 had disease control, the regimen was to be considered
worthy of further study. The sample size was calculated using
a one-sided alpha of 10% and a power of 90%. All toxicities
were graded according to the Common Terminology Criteria
for Adverse Events Version 3.0.
Study Endpoints
All endpoints were collected and analyzed for the two
patient populations (chemo-sensitive and chemo-resistant)
separately. The primary objective of the study was to estimate
the clinical benefit rate (CR, PR, SD) of pemetrexed in the
two patient populations. The secondary objectives were to
determine the toxicity, time to disease progression, and to
estimate overall survival.
Response was assessed using the Response Evaluation
Criteria in Solid Tumors criteria. Time to disease progression
was defined as time from start of treatment until the criteria
for disease progression was met. Overall survival was defined
as the number of days from the day of first treatment to death
or the last date of patient contact (whichever is earlier).
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RESULTS
Patient Characteristics
From January 2005 to September 2005, 20 chemo-
sensitive patients and 23 chemo-resistant patients were ac-
crued to the study from 14 sites within the Hoosier Oncology
Group. Two patients had extrapulmonary small cell carci-
noma, with the remaining 41 patients having SCLC. Patient
characteristics are displayed in Table 1. Criteria to proceed to
stage II was not met for either arm. The median number of
cycles of pemetrexed was 2 (range, 1–6). No dose delays or
modifications were required.
Toxicity
Grade 3/4 toxicities are summarized in Table 2. Grade
3/4 hematologic toxicities were minimal, and grade 3/4 non-
hematologic toxicities were consistent with previous data for
single agent pemetrexed.
Response and Survival
Progressive disease as the best response was noted in
16 patients in the chemo-sensitive group (80%) and 19
patients (83%) in the chemo-refractory group. In the chemo-
sensitive group, one patient (5%) achieved a partial response
and three patients (15%) achieved stable disease. In the
chemo-resistant group, one patient (4%) had a partial re-
sponse and three patients (13%) had stable disease. At the
time of final analysis (March, 2008), 17% of patients on the
trial were alive (two in each group). Median time to disease
progression in the chemo-sensitive and chemo-resistant arms
was 1.28 months (95% confidence interval CI: 0.69–1.54)
and 1.22 months (95% CI: 1.12–1.31), respectively, and
median survival time was 4.4 months (95% CI: 2.7–10.3) and
2.7 months (95% CI: 1.8–7.7), respectively.
DISCUSSION
Our study evaluated single agent pemetrexed in re-
lapsed SCLC and did not meet the predetermined criteria for
increasing the sample size to 96 patients. Response rates were
disappointing and the majority of patients had early progres-
sive disease. Single agent pemetrexed has minimal activity in
patients with previously treated SCLC, including those with
previously chemotherapy-sensitive disease.
Other investigators have reported their experience with
pemetrexed in patients with previously treated SCLC. Grøn-
berg et al.10 treated patients with pemetrexed at 900 mg/m2
and also reported minimal activity in both chemotherapy-
sensitive and chemotherapy-resistant patients (12% stable
disease and 84% progressive disease in sensitive arm, 11%
partial response and 89% progressive disease in resistant
arm). Raju et al.11 enrolled 121 patients (56 chemotherapy-
sensitive and 65 chemotherapy-resistant) with relapsed SCLC
who had received only one prior chemotherapy regimen.
Patients were treated with pemetrexed at doses ranging from
500 to 900 mg/m2. Preliminary results indicated a disappoint-
ing clinical benefit rate (CR, PR, SD) of 20% in the chemo-
therapy-sensitive arm and 21.7% in the chemo-refractory
arm. There were no responses with 500 mg/m2 and only one
partial response was seen with 900 mg/m2.
In addition, a phase III trial comparing platinum with
etoposide versus pemetrexed was closed early when an initial
analysis reported that the pemetrexed arm was unable to meet
the predefined end point of noninferiority. Interim results of
this study (known as GALES) were presented at the 2008
meeting of the American Society of Clinical Oncology. In
this study, chemonaive patients with ED SCLC were random-
ized to either the combination of pemetrexed (500 mg/m2
TABLE 1. Baseline Characteristics
Characteristics
No. of Patients (%)
Chemo-sensitive
(n  20)
Chemo-resistant
(n  23)
Age (yrs)
Median 62.5 65
Range 44–78 41–78
Sex
Male 12 (60%) 17 (74%)
Female 8 (40%) 6 (26%)
ECOG PS
0 7 (35%) 7 (30%)
1 8 (40%) 10 (44%)
2 5 (25%) 6 (26%)
Prior treatments 11 (48%)
One chemotherapy 6 (30%) 9 (39%)
Two chemotherapy 10 (50%) 3 (13%)
2 (3rd line targeted
therapy)
4 (20%)
Smoking history
Current 7 (35%) 11 (48%)
Former 12 (60%) 12 (52%)
Never 1 (5%) 0
Median time since prior
regimen (range)
149 d (28–515) 59 d (21–405)
ECOG, Eastern Cooperative Oncology Group; PS, performance status.
TABLE 2. Key Grade 3/4 Toxicities
Toxicity
Chemo-sensitive Chemo-resistant
Grade 3 Grade 4 Grade 3 Grade 4
Hematologic
Neutropenia 1 (5%) 1 (5%) 1 (4.3%) 2 (8.7%)
Thrombocytopenia 0 1 (5%) 2 (8.7%) 2 (8.7%)
Anemia 2 (10%) 0 2 (8.7%) 0
Febrile neutropenia 2 (10%) 0 0 0
Fatigue 4 (20%) 0 5 (21.7%) 0
Hyperbilirubinemia 0 1 (5%) 2 (8.7%) 0
AST elevation 2 (10%) 0 0 0
Nausea 0 0 1 (4.3%) 0
Constipation 0 0 0 1 (4.3%)
Diarrhea 1 (5%) 0 0 1 (4.3%)
Mucositis 0 0 1 (4.3%) 0
Rash 1 (5%) 0 0 0
Infection 1 (5%) 0 1 (4.3%) 0
AST, aspartate aminotransferase.
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intravenously day 1) and carboplatin (area under the curve 5
intravenously day 1) or etoposide (100 mg/m2 days 1, 2, 3)
and carboplatin (area under the curve 5 intravenously day 1).
The interim analysis included 364 patients on the pemetrexed
arm and 369 on the etoposide arm. Progression free survival
was noted to be inferior for patients on the pemetrexed arm
compared with those on standard therapy (3.68 versus 5.32
months with hazard ratio  1.79). Overall response rates
were also inferior for the pemetrexed arm (24.9% versus
40.5% with p value 0.001).12
Nearly all chemotherapy agents active against non-
SCLC are also active in SCLC. Pemetrexed seems to be an
exception to this observation. Recent evidence suggests that
tumors associated with a high expression of thymidylate
synthase may be resistant to the effects of pemetrexed.13 It
seems that squamous cell lung cancers (with high levels of
thymidylate synthase activity), for example, are resistant to
pemetrexed, whereas nonsquamous lung cancers are more
sensitive.14,15 Ceppi et al. have recently reported that thymi-
dylate synthase expression in SCLC is high.16 This may
explain why pemetrexed has minimal activity against SCLC.
There have been few advances in the systemic treat-
ment of SCLC over the last 25 years. This is due, in part, to
the lack of a comprehensive understanding of key signaling
pathways in SCLC. There is clearly a chemotherapy-sensitive
population of cells, which can be effectively treated with
many chemotherapeutics; however, there is a chemotherapy-
resistant clone, which resists most treatment and ultimately
results in the patient’s death. This level of complexity of
SCLC is underscored by data published by Davies et al.,17
who evaluated somatic mutations of the protein kinase gene
family in 26 primary lung neoplasms (seven adenocarcino-
mas, seven squamous cell carcinomas, six large cell carcino-
mas and six carcinoids) and seven lung cancer cell lines
(which included one neuroendocrine cancer). They reported
148 somatic mutations in 141 genes (higher incidence than
observed in other cancers). Most of the mutations were
thought to be passenger ones that are not believed to play a
significant role in the cancer phenotype. Nevertheless, more
than 40 nonsynonymous substitutions were detected, which
might possibly be implicated in oncogenesis (driver muta-
tions). Some heterogeneity was noted in the mutational spec-
trum among the different lung cancer cells screened in that
study as well. For example, the largest number of somatic
mutations was noted in NCI-H1770 cell line, which was
derived from a lung neuroendocrine tumor.
As illustrated by our study and those involving many
other therapies (chemotherapy and targeted agents), the con-
tinued exploration of empiric therapies is unlikely to result in
major advances for patients suffering from SCLC, and a
better understanding of the biology of the disease is greatly
needed.
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